Date Range
Date Range
Date Range
Thursday, December 23, 2010. Approval of Nilotinib Gives Patients With Newly Diagnosed Ph Chronic Myeloid Leukemia New Medical Option. In laboratory studies, nilotinib has been shown to be a potent and selective inhibitor of the Bcr-Abl protein that .
What to expect at ASCO. Changing Treatment and Follow-up Care Helps Reduce Severe Late Stage Health Problems in Pediatric Cancer Survivors. Changes in treatment and follow-up care in pediatric cancer have resulted in a decline of sever.
Is an open-access platform that publishes all aspects of research on the treatment of cancer using radiation. By disseminating research results, scientific and technical information involving radiation therapy, Oncozone. Below is a non-exhaustive list of recent scientific posters and presentations made on the subject of breast cancer treatment. Within the field of radiation oncology.
Evaluation of Intra-Fractional Patient Movement during Image-Guided Stereotactic Body Radiation Therapy of Spine and Lung Patients. Click here to access this document.